These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1913342)

  • 1. Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice.
    Elmer GW; Corthier G
    Can J Microbiol; 1991 Apr; 37(4):315-7. PubMed ID: 1913342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study.
    Castex F; Corthier G; Jouvert S; Elmer GW; Lucas F; Bastide M
    J Gen Microbiol; 1990 Jun; 136(6):1085-9. PubMed ID: 2200843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii.
    Corthier G; Dubos F; Ducluzeau R
    Can J Microbiol; 1986 Nov; 32(11):894-6. PubMed ID: 3815159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
    Castagliuolo I; Riegler MF; Valenick L; LaMont JT; Pothoulakis C
    Infect Immun; 1999 Jan; 67(1):302-7. PubMed ID: 9864230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model.
    Geeraerts S; Ducatelle R; Haesebrouck F; Van Immerseel F
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1275-80. PubMed ID: 25800047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants.
    Buts JP; Corthier G; Delmee M
    J Pediatr Gastroenterol Nutr; 1993 May; 16(4):419-25. PubMed ID: 8315551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clostridium difficile typhlitis associated with cecal mucosal hyperplasia in Syrian hamsters.
    Ryden EB; Lipman NS; Taylor NS; Rose R; Fox JG
    Lab Anim Sci; 1991 Dec; 41(6):553-8. PubMed ID: 1667196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental effects of Saccharomyces boulardii on diarrheal pathogens.
    Czerucka D; Rampal P
    Microbes Infect; 2002 Jun; 4(7):733-9. PubMed ID: 12067833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile-induced colonic secretion in the rat.
    Izadnia F; Wong CT; Kocoshis SA
    Dig Dis Sci; 1998 Sep; 43(9):2055-60. PubMed ID: 9753273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of toxins produced by various Clostridium difficile strains on cecum size reduction in gnotobiotic mice.
    Mahé S; Corthier G
    Can J Microbiol; 1988 Jul; 34(7):916-8. PubMed ID: 3143476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.
    Kimmey MB; Elmer GW; Surawicz CM; McFarland LV
    Dig Dis Sci; 1990 Jul; 35(7):897-901. PubMed ID: 2364845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of a mixture of kefir-isolated lactic acid bacteria and yeasts in a hamster model of Clostridium difficile infection.
    Bolla PA; Carasi P; Bolla Mde L; De Antoni GL; Serradell Mde L
    Anaerobe; 2013 Jun; 21():28-33. PubMed ID: 23542116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study.
    Can M; Beşirbellioglu BA; Avci IY; Beker CM; Pahsa A
    Med Sci Monit; 2006 Apr; 12(4):PI19-22. PubMed ID: 16572062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters.
    Elmer GW; McFarland LV
    Antimicrob Agents Chemother; 1987 Jan; 31(1):129-31. PubMed ID: 3566236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clostridium difficile colitis.
    Fang FC; Madinger NE
    N Engl J Med; 1994 Jun; 330(24):1754; author reply 1755. PubMed ID: 8190139
    [No Abstract]   [Full Text] [Related]  

  • 16. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii.
    Hassett J; Meyers S; McFarland L; Mulligan ME
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S266-8. PubMed ID: 7548571
    [No Abstract]   [Full Text] [Related]  

  • 17. Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection.
    Flatley EA; Wilde AM; Nailor MD
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):21-4. PubMed ID: 25822430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of various diets on toxin production by two strains of Clostridium difficile in gnotobiotic mice.
    Mahe S; Corthier G; Dubos F
    Infect Immun; 1987 Aug; 55(8):1801-5. PubMed ID: 3610315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridium difficile and its cytotoxin in diarrhoeic stools of hospitalized patients. Toxigenic potential of the isolates.
    De Barbeyrac B; Guinet R; Quentin C; Cantet P; Bebear C
    Ann Biol Clin (Paris); 1989; 47(2):67-70. PubMed ID: 2660635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of oral Saccharomyces boulardii treatment on the activity of Clostridium difficile toxins in mouse digestive tract.
    Corthier G; Lucas F; Jouvert S; Castex F
    Toxicon; 1992 Dec; 30(12):1583-9. PubMed ID: 1488767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.